PIK3CA and cervical carcinoma: PIK3CA mutations occurred most frequently in the overall patient group, and the mutation rate in our study was higher than the rates in previous studies of cervical carcinoma from the Netherlands (20%), France (27%), Latin America (28–33%), the USA (31%) and Norway (15%) [3, 21–24].